CA3166738A1 — Travoprost compositions and methods for treating ocular diseases
Assigned to Ocular Therapeutix Inc · Expires 2021-08-12 · 5y expired
What this patent protects
There is described an intracameral implant, its use to treat various ocular diseases and a method for producing it. In a preferred embodiment the implant has a prescribed length/diameter and comprises:a biodegradable hydrogel, wherein the hydrogel comprises a polymer network comp…
USPTO Abstract
There is described an intracameral implant, its use to treat various ocular diseases and a method for producing it. In a preferred embodiment the implant has a prescribed length/diameter and comprises:a biodegradable hydrogel, wherein the hydrogel comprises a polymer network comprising one or more units of polyalkylene glycol, and travoprost particles having a prescribed average diameter,the travoprost particles being in the form of travoprost intermixed with a biodegradable polymer, andthe travoprost particles being dispersed within the hydrogel, wherein the implant has a prescribed fixed dose of travoprost.There is reported a clinical study in which the implant is demonstrated to: achieve lowering of intraocular pressure (IOP), stay in place and maintain endothelial health.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.